Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAP-486 for ventricular arrhythmias
NCT00124891Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2005
- Primary completion
- Nov 2006
- Modality
- Peptides, Small Molecules
- Countries
- 16
01
Overview
Phase 2, double-blind trial of rotigaptide in ventricular arrhythmias (2 arms), sponsored by Pfizer. Primary endpoint: The total number of ventricular beats recorded by Holter monitoring during the 24 hr. on-therapy phase. Started Jun 2005; status: terminated.
02
Drugs
rotigaptide
03
Conditions
ventricular arrhythmias
Beyond the preview
Go deeper on NCT00124891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124891.